Effect of Salmeterol/fluticasone on Interleukin-32 Expression in Induced Sputum and Plasma of Stable Chronic Obstructive Pulmonary Disease

DU Yi-peng,WANG Wei,YANG Wei,HE Bei

DOI: https://doi.org/10.3760/cma.j.issn.1673-436x.2011.003.005

2011-01-01

Abstract:Objective The interleukin-32(IL-32), a newly discovered cytokine, was reported to have increased expressions in the lung tissue of patients with chronic obstructive pulmonary disease (COPD) and correlated with the degree of airflow obstructions. This study was to undertake a randomized controlled trail to evaluate combined salmeterol/fluticasone on IL-32 and inflammatory cells in induced sputum and plasma of COPD patients and discuss whether IL-32 is related to the inflammatory disorder of COPD patients. Methods Using enzyme-linked immunosorbent assay, the expression of IL-32 in induced sputum and plasma was respectively examined to the following groups: 32 patients with stable COPD, 18 asymptomatic smokers, and 18 nonsmokers. COPD patients were treated in an open-labeled, randomized,parallel group and controlled trial with either a combination of 50 μg salmeterol and 500 μg fluticasone twice daily (SF, n = 18) or 21 μg salbutamol and 120 μg ipratropine quartic daily (IS, n = 18) for 3 months. At the start and end of treatment induced sputum was performed and the level of IL-32 was measured. Results IL-32 level in sputum and plasma of the four groups did not show significant differences. IL-32 level in sputum had no correlation to macrophage and neutrophil count in sputum,FEV1% predicted and SGRQ. IL-32 level in plasma of COPD patients had positive correlation to TNF-α level in plasma ( r=0. 65, P＜0. 001). In addition, SGRQ was significantly reduced by SF ( P＜0. 001)which was not seen with IS. SF did not significantly change IL-32 level in sputum and plasma,macrophage and neutrophil count in sputum and FEV1 % predicted compared with IS. Conclusions The results of this study suggested that although IL-32 was not related to the increase of inflammatory cells in induced sputum of COPD patients, it might be implicated in the systematic inflammatory disorder of COPD patients. SF improved the health status but did not significantly change IL-32 level and inflammatory cells in induced sputum of COPD patients.